Study Site Information
Semel Institute at the University of California Los Angeles
Keith Nuechterlein, PhD
Dr. Nuechterlein is a Professor of Psychiatry and Biobehavioral Sciences and the Director of the Aftercare Research Program at the UCLA Semel Institute for Neuroscience and Human Behavior. His primary research interest focuses on interventions to improve the early course of schizophrenia. Dr. Nuechterlein is the Co- PI at the UCLA site, where he co-leads and coordinates the recruitment and assessments of participants into the PBN.
Carrie E. Bearden, PhD
Dr. Bearden is a Professor of Psychiatry and Biobehavioral Sciences & Psychology, and the Director of the Center for the Assessment and Prevention of Prodromal States (CAPPS) program at the UCLA Semel Institute for Neuroscience and Human Behavior. She is interested in early brain biomarkers predictive of psychosis and other serious mental illness. Dr. Bearden provides scientific leadership to the PBN and is the Co- PI for the PBN study at the UCLA site.Information about research programs at the UCLA Semel Institute can be found at CAPPS website, Dr. Bearden's lab website and the After Care program website.
Yale School of Medicine
Mohini Ranganathan, MD
Dr. Ranganathan is Associate Professor at Yale School of Medicine and a board-certified psychiatrist at VA Connecticut Healthcare System where she directs the interventional psychiatry service. Her research focused on the effects of cannabinoids on psychosis- both the risks of cannabinoid exposure as well as potentially beneficial cannabinoids. Dr. Ranganathan has been the site PI at Yale for PBN since the beginning of the study and is also as a member of the Biospecimen Resource Access Committee.Contact Information
Icahn School of Medicine at Mt. Sinai
Cheryl Corcoran, MD
Dr. Corcoran is the Associate Professor and Program Leader in Psychosis Risk at the Icahn School of Medicine at Mount Sinai. She is an expert in schizophrenia, including its clinical characterization. Dr. Corcoran has been the PI of the PBN data collection site at Mount Sinai from the beginning of our study. She is also a member of the Samples, Assays & Analytes working group.
Contact Information
The Feinstein Institutes for Medical Research, Northwell Health
Juan A. Gallego, MD, MS
Dr. Gallego is the Director of the Early Phase Schizophrenia Biomarker Laboratory at the Zucker Hillside Hospital. He is interested in cerebrospinal fluid and plasma biomarkers in schizophrenia. Dr. Gallego is the PI at the Northwell PBN site where he leads and coordinates the recruitment of all participants into the PBN.
Contact Information
Perelman School of Medicine Hospital of the University of Pennsylvania
Raquel Gur, MD, PhD
Dr. Gur is Professor of Psychiatry Neurology and Radiology at the University of Pennsylvania Perelman School of Medicine where she directs the Neurodevelopment and Psychosis Section of Psychiatry and the Lifespan Brain Institute. Her research group integrates phenotypic parameters of brain and behavior in common and rare variants taking a lifespan perspective. She provides scientific leadership for the PBN, she has been a member of a data collecting site in the network from its inception contributing to translational research effort and integration across sites.
Christian Kohler, MD
Dr. Kohler is a Professor of Psychiatry and Neurology at the University of Pennsylvania Perelman School of Medicine. He directs the early psychosis intervention program for young persons with first-episode psychosis and clinical-high risk.His research is focused on the area of emotion processing in healthy people and patients with brain disorders. Dr. Kohler provides advice on the clinical aspects of the study design and has been a Co-PI at UPenn for PBN from the start of the study.
Contact Information
::